KRAS and pancreatic intraductal papillary-mucinous neoplasm: Therefore, in this meta-analysis, we aimed to know the exact prevalence of KRAS, GNAS, and RNF43 mutations in IPMN patients, and the difference between the frequency of these mutant genes in pancreatic cystic lesions.